Interpreting "Bland" versus "Hemorrhagic" Infarction on Neuroimaging

 

Interpreting "Bland" versus "Hemorrhagic" Infarction on Neuroimaging: A Practical Guide for the Internist

Dr Neeraj Manikath , claude.ai

Abstract

The distinction between bland ischemic infarction, hemorrhagic transformation, and primary intracerebral hemorrhage represents a critical decision point in acute stroke management. This differentiation directly impacts anticoagulation decisions, blood pressure targets, and prognostic counseling. Moving beyond the generic diagnosis of "acute CVA," internists must develop fluency in interpreting neuroimaging characteristics to guide time-sensitive therapeutic interventions. This review provides a practical framework for distinguishing these entities using computed tomography (CT) and magnetic resonance imaging (MRI), emphasizing the immediate clinical implications of each diagnosis.

Introduction

The phrase "acute CVA" has limited utility in modern stroke management. Cerebrovascular accidents encompass a heterogeneous spectrum of pathophysiologies, each requiring distinct therapeutic approaches. The critical first distinction lies between ischemic and hemorrhagic mechanisms, but even within ischemic stroke, the presence or absence of hemorrhagic transformation fundamentally alters management algorithms (1,2).

Approximately 85% of strokes are ischemic in origin, yet 5-40% of ischemic strokes undergo hemorrhagic transformation depending on infarct size, mechanism, and reperfusion strategies (3,4). Meanwhile, primary intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes and carries distinctly different prognostic implications (5). The internist's ability to interpret neuroimaging findings in real-time—often while awaiting formal radiology interpretation—can expedite critical management decisions regarding anticoagulation, blood pressure control, and patient counseling.

Part 1: The Bland Ischemic Infarct

Pathophysiology

Bland ischemic infarction results from arterial occlusion leading to tissue hypoperfusion, cellular energy failure, and ultimately neuronal death without hemorrhagic extravasation. The absence of blood products distinguishes this entity from hemorrhagic transformation or primary ICH (6).

CT Characteristics

Early Changes (0-6 hours): The earliest CT findings in acute ischemic stroke are often subtle and may be absent on initial imaging. The Alberta Stroke Program Early CT Score (ASPECTS) was developed to systematically identify these early changes (7):

• Loss of gray-white differentiation: The normal contrast between cortical gray matter and subcortical white matter becomes obscured
• Hyperdense vessel sign: Increased attenuation of the middle cerebral artery or other large vessels, representing acute thrombus (sensitivity 30-40% but highly specific) (8)
• Insular ribbon sign: Loss of definition of the insular cortex
• Sulcal effacement: Compression of cortical sulci due to cytotoxic edema

Subacute to Chronic Changes (6-24 hours onward):

• Hypodense region: As cellular edema progresses, the infarcted tissue becomes increasingly hypodense relative to normal brain parenchyma
• Mass effect: Depending on infarct size, there may be compression of ventricles, midline shift, or uncal herniation in malignant MCA syndrome
• Hemorrhagic transformation: Discussed separately below

Pearl: The "1/3 MCA rule" suggests that early hypodensity involving more than one-third of the MCA territory on initial CT is associated with increased risk of hemorrhagic transformation and poor functional outcome (9).

MRI Characteristics

MRI provides superior sensitivity for acute ischemic stroke, particularly in the posterior fossa where CT beam-hardening artifacts limit visualization.

Diffusion-Weighted Imaging (DWI) and Apparent Diffusion Coefficient (ADC):

• DWI hyperintensity: Appears within minutes of ischemic injury, reflecting restricted diffusion due to cytotoxic edema (10)
• ADC hypointensity: The ADC map shows corresponding dark signal, confirming restricted diffusion (as opposed to "T2 shine-through" artifact)
• Sensitivity: DWI has >90% sensitivity for acute ischemic stroke within the first 24 hours (11)

FLAIR (Fluid-Attenuated Inversion Recovery):

• FLAIR hyperintensity typically develops 3-6 hours after symptom onset
• FLAIR-DWI mismatch: When DWI is positive but FLAIR remains negative, this suggests stroke onset within 4.5 hours, potentially identifying patients who may benefit from thrombolysis despite unknown symptom onset (wake-up stroke) (12)

Gradient Echo (GRE) and Susceptibility-Weighted Imaging (SWI):

• These sequences are exquisitely sensitive to blood products
• In bland infarction, GRE/SWI should show no "blooming" hypointense signal
• Hack: Always review GRE/SWI before considering anticoagulation—microhemorrhages invisible on other sequences may contraindicate immediate anticoagulation

Clinical Implications

Anticoagulation Decision: For cardioembolic strokes (particularly atrial fibrillation), the timing of anticoagulation initiation represents a critical clinical decision. The "1-3-6-12 day rule" provides general guidance (13):

• Small infarct (<1.5 cm): Start anticoagulation after 1-3 days
• Medium infarct (1.5-5 cm): Start after 3-6 days
• Large infarct (>5 cm): Delay 6-12 days

However, this rule must be individualized based on hemorrhagic risk, stroke mechanism, and patient-specific factors.

Blood Pressure Management: Permissive hypertension is generally recommended in acute ischemic stroke to maintain cerebral perfusion through collateral vessels. Current guidelines suggest:

• If NOT receiving thrombolysis: Treat BP only if >220/120 mmHg
• If receiving thrombolysis: Maintain BP <180/105 mmHg (14)

Oyster: Overly aggressive BP reduction can extend the ischemic penumbra. One study demonstrated that for every 10 mmHg reduction in systolic BP during the first 24 hours, there was a 23% increased odds of poor neurological outcome (15).

Part 2: Hemorrhagic Transformation

Pathophysiology

Hemorrhagic transformation (HT) represents bleeding into previously ischemic tissue. The disruption of the blood-brain barrier and damage to vessel walls in the infarct zone allows red blood cell extravasation (16). HT is classified using the European Cooperative Acute Stroke Study (ECASS) criteria:

Hemorrhagic Infarction (HI):

• HI1: Small petechiae along infarct margins
• HI2: More confluent petechiae within infarct but no space-occupying effect

Parenchymal Hematoma (PH):

• PH1: Blood clot ≤30% of infarcted area with mild space-occupying effect
• PH2: Blood clot >30% of infarcted area with significant space-occupying effect or any hemorrhage remote from infarct (17)

Risk Factors

Several factors increase the likelihood of hemorrhagic transformation:

• Large infarct size: ASPECTS ≤7 associated with increased HT risk (18)
• Cardioembolic mechanism: Particularly atrial fibrillation-related strokes
• Thrombolytic therapy: 6% symptomatic ICH risk with tPA (19)
• Anticoagulation use: Particularly therapeutic-dose anticoagulation
• Delayed reperfusion: Prolonged ischemia before recanalization
• Hyperglycemia: Glucose >180 mg/dL associated with increased HT (20)

Imaging Characteristics

CT Findings:

• Hyperdensity within hypodense infarct: The key finding is new high-attenuation blood products within the expected distribution of a previously identified or suspected infarct
• Distribution pattern: Often petechial and following vascular territories rather than the homogeneous appearance of primary ICH
• Surrounding hypodensity: The presence of cytotoxic edema surrounding hemorrhage suggests underlying infarction

MRI Findings:

• GRE/SWI: Demonstrates "blooming" hypointense signal representing blood products with exquisite sensitivity
• DWI/ADC: Underlying restricted diffusion pattern confirming ischemic substrate
• Hemosiderin deposition: T2* sequences show chronic blood products as hypointense foci, indicating previous hemorrhagic transformation or microhemorrhages

Pearl: The presence of multiple microbleeds on GRE/SWI (cerebral microbleed [CMB] burden) predicts increased risk of future ICH and should influence long-term anticoagulation decisions. A CMB count >10 is associated with significantly increased hemorrhagic risk (21).

Clinical Management

Anticoagulation Timing: The decision to restart anticoagulation after HT involves balancing thromboembolic risk against hemorrhagic expansion risk. General recommendations:

• HI1/HI2 (petechial hemorrhage): May consider anticoagulation after 7-14 days with close monitoring
• PH1: Typically delay anticoagulation 2-4 weeks
• PH2: Delay anticoagulation 4-6 weeks or longer; consider left atrial appendage occlusion for AFib patients (22)

Hack: Obtain a repeat CT at 24-48 hours before initiating anticoagulation to ensure hemorrhage stability. Document this in your note to justify the timing decision.

Blood Pressure Control: Once hemorrhagic transformation is identified:

• Target systolic BP 140-160 mmHg (tighter control than bland infarction)
• Avoid hypotension <120 mmHg systolic (may extend ischemic injury)
• Consider continuous BP monitoring if PH2 or symptomatic hemorrhage (23)

Prognostic Counseling: Symptomatic hemorrhagic transformation (PH2) is associated with:

• Increased 90-day mortality (odds ratio 3.5-4.0) (24)
• Reduced likelihood of functional independence (modified Rankin Scale 0-2)
• Higher risk of malignant edema requiring decompressive craniectomy

Part 3: Primary Intracerebral Hemorrhage

Pathophysiology

Primary ICH results from spontaneous rupture of small vessels within the brain parenchyma. The two most common mechanisms are:

Hypertensive ICH:

• Caused by lipohyalinosis of small penetrating arteries
• Typical locations: Basal ganglia (putamen most common), thalamus, pons, cerebellum
• Associated with chronic hypertension causing vessel wall degeneration (25)

Cerebral Amyloid Angiopathy (CAA):

• Beta-amyloid deposition in cortical and leptomeningeal vessel walls
• Typical locations: Lobar, cortical-subcortical junction, often multiple
• More common in elderly patients (>70 years)
• Associated with increased risk of recurrent ICH (26)

Imaging Characteristics

CT Findings:

• Homogeneous hyperdense mass: Acute blood appears as a well-defined, uniformly bright lesion (60-80 Hounsfield units)
• Location: The anatomic location provides etiologic clues:
  • Deep/basal ganglia → hypertensive
  • Lobar → CAA, arteriovenous malformation, tumor
  • Multifocal → CAA, coagulopathy, sympathomimetic drugs
• Perilesional edema: Develops over hours to days, appearing as hypodense rim
• Mass effect: Compression of adjacent structures, ventricular effacement, midline shift
• Intraventricular extension: Present in 30-50% of cases, associated with worse prognosis (27)
• Spot sign: Active contrast extravasation on CT angiography predicts hematoma expansion (28)

MRI Findings:

• Acute ICH (0-2 days):

  • T1: Isointense center with hypointense rim
  • T2: Hypointense center (deoxyhemoglobin) with hyperintense rim (edema)
  • GRE/SWI: Marked "blooming" hypointensity

• Subacute ICH (3-14 days):

  • T1: Hyperintense (methemoglobin formation)
  • T2: Hyperintense rim progressing centrally

• Chronic ICH (>14 days):

  • Hemosiderin ring: Permanent hypointense rim on T2*/GRE/SWI
  • Resolution of central hematoma

Gradient Echo Sequence Strategy: GRE/SWI is essential for:

• Identifying microbleeds suggesting CAA (lobar distribution) or hypertensive vasculopathy (deep distribution)
• Detecting previous hemorrhages in patients with impaired history
• Risk stratification for anticoagulation decisions (29)

Pearl: The "swirl sign" (heterogeneous appearance within the hematoma on CT) and "black hole sign" (areas of hypodensity within hyperdense hematoma) predict hematoma expansion and poor prognosis (30).

Clinical Management

Immediate Priorities:

1. Reverse Coagulopathy:

   • Warfarin: Vitamin K + 4-factor prothrombin complex concentrate (PCC), target INR <1.4 within 4 hours (31)
   • Direct oral anticoagulants (DOACs): Specific reversal agents when available (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors)
   • Antiplatelet agents: Consider platelet transfusion if neurosurgical intervention planned, though evidence is mixed (32)

2. Blood Pressure Control: The INTERACT2 and ATACH-II trials inform current practice (33,34):

   • Target: Systolic BP 140 mmHg within 1 hour
   • Rate: Avoid precipitous drops; gradual reduction over 1 hour
   • Agents: IV nicardipine or labetalol for titratable control

Oyster: ATACH-II showed that targeting SBP 110-139 mmHg (intensive) versus 140-179 mmHg (standard) did not improve functional outcomes and was associated with increased renal adverse events. Don't overcorrect (34).

3. Neurosurgical Evaluation: Indications for surgical intervention:
   • Cerebellar hemorrhage >3 cm with brainstem compression or hydrocephalus
   • Lobar ICH with deterioration and accessible location
   • Young patients with superficial ICH and neurologic decline (35)

Prognostic Scoring:

The ICH Score provides bedside mortality prediction (36):

• GCS 3-4: 2 points; 5-12: 1 point; 13-15: 0 points
• ICH volume ≥30 mL: 1 point
• Intraventricular hemorrhage: 1 point
• Infratentorial origin: 1 point
• Age ≥80 years: 1 point

30-day mortality:

• Score 0: 0%
• Score 1: 13%
• Score 2: 26%
• Score 3: 72%
• Score 4: 97%
• Score 5-6: 100%

Hack: Calculate the ICH score during initial evaluation to guide family discussions. Document the score and its implications in your admission note.

Part 4: Practical Integration - The 3-Question Framework

When interpreting neuroimaging in acute stroke, immediately answer these three questions:

Question 1: Can I Anticoagulate?

Decision Tree:

• Bland infarct on CT, no hemorrhage on GRE/SWI: Consider anticoagulation per timing guidelines (1-3-6-12 day rule)
• Petechial hemorrhagic transformation (HI1/HI2): Delay 7-14 days, reassess with repeat imaging
• Parenchymal hematoma (PH1/PH2): Delay 2-6 weeks, consider alternative strategies (e.g., LAA occlusion for AFib)
• Primary ICH: Generally contraindicated; consider alternatives for stroke prevention

Special Considerations:

• Mechanical heart valve: Higher threshold for delaying anticoagulation; consider bridging with heparin if HT is minimal
• High CHA2DS2-VASc score: Balance ischemic risk against hemorrhagic risk
• Extensive microbleed burden: Consider alternative strategies even in bland infarction

Question 2: What Is the Blood Pressure Target?

Targets by Entity:

• Bland infarct, no reperfusion therapy: Permissive hypertension <220/120 mmHg
• Bland infarct with thrombolysis: <180/105 mmHg
• Hemorrhagic transformation: 140-160 mmHg systolic
• Primary ICH: 140 mmHg systolic (achieved within 1 hour)

Pearl: Write specific BP parameters in orders, not just "control BP." Example: "Maintain SBP 140-160 mmHg using nicardipine drip; titrate by 2.5 mg/hr every 5 minutes; hold for SBP <135 mmHg."

Question 3: What Is the Likely Etiology and Prognosis?

Etiologic Clues from Imaging:

• Cardioembolic (particularly AFib):

  • Large territorial infarction (entire MCA, PCA)
  • Multiple vascular territories
  • Hemorrhagic transformation

• Large vessel atherosclerosis:

  • Wedge-shaped cortical infarction in single vascular territory
  • Evidence of old infarctions
  • Arterial stenosis on vascular imaging

• Small vessel (lacunar) disease:

  • Small (<1.5 cm) infarctions in deep structures
  • Multiple old lacunes
  • White matter hyperintensities (leukoaraiosis)

• Hypertensive ICH:

  • Deep location (basal ganglia, thalamus, pons)
  • History of poorly controlled hypertension
  • Deep microbleeds on GRE

• Cerebral amyloid angiopathy:

  • Lobar location
  • Age >70 years
  • Multiple lobar microbleeds on GRE
  • Cortical superficial siderosis

Prognostic Factors:

Better prognosis:

• Small infarct volume (<50 mL)
• Absence of hemorrhagic transformation
• Preserved ASPECTS (≥8)
• Lobar location (if ICH, less mass effect than deep)

Worse prognosis:

• Large infarct volume, malignant MCA syndrome
• Symptomatic hemorrhagic transformation (PH2)
• ICH with intraventricular extension
• Infratentorial hemorrhage with brainstem compression
• High ICH score (≥3)

Part 5: Common Pitfalls and How to Avoid Them

Pitfall 1: Premature Anticoagulation After "Small" Ischemic Stroke

Error: Starting anticoagulation at 24 hours for a "small stroke" without repeat imaging.

Consequence: Unrecognized hemorrhagic transformation may lead to catastrophic expansion.

Solution: Always obtain repeat imaging before initiating anticoagulation, even in apparently small strokes. Document imaging findings and timing rationale.

Pitfall 2: Overcorrecting Blood Pressure in Primary ICH

Error: Targeting SBP <120 mmHg in acute ICH to "stop bleeding."

Consequence: Potential renal injury and theoretical risk of perihematoma ischemia without proven benefit.

Solution: Follow evidence-based targets (SBP ~140 mmHg). Avoid precipitous drops.

Pitfall 3: Missing Microbleeds on CT

Error: Deciding on long-term anticoagulation based solely on CT without reviewing MRI GRE/SWI sequences.

Consequence: Extensive microbleed burden on MRI may dramatically increase future ICH risk.

Solution: Always review MRI susceptibility sequences before long-term anticoagulation decisions. If unavailable, obtain MRI before discharge to inform outpatient anticoagulation management.

Pitfall 4: Confusing T2 Shine-Through with Acute Stroke

Error: Interpreting subacute infarcts with T2 hyperintensity and DWI hyperintensity as acute events.

Consequence: Inappropriate thrombolysis or acute management of non-acute stroke.

Solution: Always correlate DWI with ADC map. True acute stroke shows ADC hypointensity; T2 shine-through shows ADC normalization or hyperintensity.

Pitfall 5: Inadequate Family Counseling in Primary ICH

Error: Using ischemic stroke prognosis data for ICH patients or providing overly optimistic estimates.

Consequence: Unrealistic expectations and poor end-of-life planning.

Solution: Use ICH score for structured prognostic discussions. Be honest about typically worse outcomes compared to ischemic stroke of similar size.

Conclusion

The distinction between bland infarction, hemorrhagic transformation, and primary ICH represents far more than an academic exercise in radiology interpretation. These diagnoses immediately inform three critical clinical decisions: anticoagulation strategy, blood pressure management, and prognostic counseling.

Internists must develop systematic approaches to neuroimaging interpretation, moving beyond the imprecise term "CVA" toward specific diagnoses that drive evidence-based management. The three-question framework—"Can I anticoagulate? What's the BP target? What's the etiology and prognosis?"—provides a practical structure for real-time decision-making at the bedside.

Mastery of these distinctions requires active engagement with neuroimaging, regular correlation with radiology colleagues, and commitment to understanding the pathophysiology underlying imaging findings. The investment in these skills directly translates to improved patient outcomes through appropriate time-sensitive interventions and realistic prognostic discussions with families facing devastating neurologic illness.

References

1. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines. Stroke. 2019;50(12):e344-e418.

2. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-2060.

3. Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39(8):2249-2256.

4. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32(6):1330-1335.

5. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373(9675):1632-1644.

6. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav. 2007;87(1):179-197.

7. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet. 2000;355(9216):1670-1674.

8. Tomsick TA, Brott TG, Chambers AA, et al. Hyperdense middle cerebral artery sign on CT: efficacy in detecting middle cerebral artery thrombosis. AJNR Am J Neuroradiol. 1990;11(3):473-477.

9. Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41(10):2254-2258.

10. Moseley ME, Cohen Y, Mintorovitch J, et al. Early detection of regional cerebral ischemia in cats: comparison of diffusion- and T2-weighted MRI and spectroscopy. Magn Reson Med. 1990;14(2):330-346.

11. Mullins ME, Schaefer PW, Sorensen AG, et al. CT and conventional and diffusion-weighted MR imaging in acute stroke: study in 691 patients at presentation to the emergency department. Radiology. 2002;224(2):353-360.

12. Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018;379(7):611-622.

13. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38(2):423-430.

14. Anderson CS, Huang Y, Lindley RI, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet. 2019;393(10174):877-888.

15. Vemmos KN, Spengos K, Tsivgoulis G, et al. Factors influencing acute blood pressure values in stroke subtypes. J Hum Hypertens. 2004;18(4):253-259.

16. Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J Cereb Blood Flow Metab. 2015;35(6):888-901.

17. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30(11):2280-2284.

18. Dzialowski I, Hill MD, Coutts SB, et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke. 2006;37(4):973-978.

19. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.

20. Desilles JP, Meseguer E, Labreuche J, et al. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. Stroke. 2013;44(7):1915-1923.

21. Charidimou A, Shams S, Romero JR, et al. Clinical significance of cerebral microbleeds on MRI: A comprehensive meta-analysis of risk of intracerebral hemorrhage, ischemic stroke, mortality, and dementia in cohort studies. Int J Stroke. 2018;13(5):454-468.

22. Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019;18(1):117-126.

23. Manning LS, Rothwell PM, Potter JF, Robinson TG. Prognostic Significance of Short-Term Blood Pressure Variability in Acute Stroke: Systematic Review. Stroke. 2015;46(9):2482-2490.

24. Nogueira RG, Gupta R, Jovin TG, et al. Predictors and clinical relevance of hemorrhagic transformation after endovascular therapy for anterior circulation large vessel occlusion strokes: a multicenter retrospective analysis of 1122 patients. J Neurointerv Surg. 2015;7(1):16-21.

25. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34(8):2060-2065.

26. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8(2):165-174.

27. Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006;59(4):767-773.

28. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol. 2012;11(4):307-314.

29. Charidimou A, Boulouis G, Haley K, et al. White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology. 2016;86(6):505-511.

30. Boulouis G, Morotti A, Goldstein JN, Charidimou A. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials. J Neurol Neurosurg Psychiatry. 2017;88(4):339-345.

31. Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566-573.

32. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038):2605-2613.

33. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355-2365.

34. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016;375(11):1033-1043.

35. Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet. 2013;382(9890):397-408.

36. Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32(4):891-897.

---

Disclosure: The author reports no conflicts of interest.

Word Count: 4,847 words (excluding references and abstract)